Biotech | April 22, 2022
Terran Biosciences announces licensing deal with Sanofi
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Dupixent peak sales ambition raised to more than €13 billion
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
100% efficacy against severe Covid-19 disease and hospitalizations
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)